%0 Journal Article
%T Do we need a re-TUR after en bloc resection of T1 stage bladder cancer?
%A Levy S
%A Péricart S
%A Bajeot AS
%A Fakhfakh S
%A Lesourd M
%A Soulié M
%A Pignot G
%A Roumiguié M
%J World J Urol
%V 42
%N 1
%D 2024 Aug 8
%M 39115589
%F 3.661
%R 10.1007/s00345-024-05175-y
%X <B>BACKGROUND: </B>A second look trans-urethral resection of the bladder (re-TUR) is recommended after the diagnosis of T1 high grade (T1HG) bladder cancer. Few studies have evaluated the results of re-TUR after a first en bloc resection (EBR) and none of them have specifically reported the pathological results on the field of previous T1 disease.<BR><B>OBJECTIVE: </B>To report the rate of upstaging and the rate of residual disease (RD) on the field of T1HG lesions resected with EBR.<BR><B>METHODS: </B>Between 01/2014 and 06/2022, patients from 2 centers who had a re-TUR after an EBR for T1HG urothelial carcinoma were retrospectively included. Primary endpoint was the rate of RD including the rate of upstaging to T2 disease on the scar of the primary resection. Secondary endpoints were the rate of any residual disease outside the field.<BR><B>RESULTS: </B>Seventy-five patients were included. No muscle invasive bladder cancer lesions were found after re-TUR. Among the 16 patients who had a RD, 4 were on the resection scar. All of these lesions were papillary and high grade. RD outside the field of the first EBR was observed in 12 patients.<BR><B>CONCLUSIONS: </B>After EBR of T1HG disease, none of our patients had an upstaging to MIBC. However, the rate of RD either on and outside the field of the EBR remains quite significant. We suggested that predictive factors of residual papillary disease (number of tumors at the initial TUR and concomitant CIS) might be suitable to select patient who will benefit of the re-TUR.